Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 –seamlessly integrated into the clinical workflow– has the potential to transform a routine tumor ablation into a systemic immunotherapy to fight cancer throughout the body. Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President are pleased to announce...
We are thrilled to announce that Dr. Robert Martin has successfully enrolled and treated the first patient in our groundbreaking clinical trial: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma after Complete Radiological Response following Surgical Resection and Local Ablation or Local...
Immunophotonics is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific research, received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics’ advanced ablation devices. This trial will explore the power of IP-001 following thermal ablation or irreversible...
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a partnership that will combine use of Immunophotonics’ lead asset, IP-001 and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers. This collaborative effort extends to a partnership with the Cancer...
St. Louis cancer drug startup Immunophotonics Inc. will pursue expansion of its lead drug candidate through a partnership with the innovation arm of pharmaceutical giant Johnson & Johnson. (St. Louis INNO/Business Journal article)
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a research collaboration with Johnson & Johnson Enterprise Innovation Inc. (JJEI) to explore the use of radiation in conjunction with Immunophotonics’ lead drug candidate, IP-001, as a novel immunotherapy approach for the treatment of solid tumor cancers. This collaboration agreement represents a...
Immunophotonics CEO Lu Alleruzzo announced, along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal Investigator and National Coordinating Investigator at the University of Louisville, that the first patient has been dosed with IP-001 in the United States under Immunophotonics’ Investigational New Drug (IND) application with the FDA. The U.S....
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at Hôpital Foch in Suresnes. The protocol has been approved within the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating. The principal objective of this study is to...
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The patient was treated as part of a multinational clinical trial sponsored by Immunophotonics (IP-IIO-622) that will assess the safety and efficacy of its lead asset, IP-001. The protocol has been approved by regulatory authorities in...
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the United Kingdom at the University College London. This multinational clinical trial sponsored by Immunophotonics will assess the safety and efficacy of its lead asset, IP-001, and is currently enrolling patients for treatment of colorectal cancer,...
